The transcription factor FoxO3 contributes to anti-hypertrophic signalling in the heart presumably by regulating autophagic-lysosomal and ubiquitin-proteasomal pathways. We wanted to study FoxO3 function in the adult heart in vivo by expressing a constitutively active mutant of FoxO3 in transgenic mice.
Introduction
The heart shows considerable plasticity when challenged by physiological or pathological stimuli. Medical research is primarily directed towards heart hypertrophy, which occurs in various disease settings and is associated with high mortality. In contrast, heart atrophy, which occurs under prolonged bed rest, in patients suffering from anorexia or in patients with mechanical unloading of the heart, is less well understood. As heart atrophy and hypertrophy are governed by similar pathways, an understanding of heart atrophy may also contribute to an elucidation of the mechanisms of heart hypertrophy.
Since the proliferative capacity of adult cardiomyocytes is very limited, the regulation of heart size is principally based on hypertrophy and atrophy at the cellular level. Thus, the balance between pro-and anti-growth signals in the individual cardiomyocyte is crucial for the homeostasis of the whole organ. Among the pathways regulating heart size, the insulin/PI3K/AKT and the calcineurin/NFAT pathways are prominent. 1 For example, cardiac-specific deletion of the insulin receptor leads to heart atrophy, which is based on a reduction in the size of individual myocytes. 2 Accordingly, expression of a dominant-negative PI3K mutant results in decreased organ and myocyte size, whereas expression of a constitutively active PI3K mutant results in increased organ and myocyte size. 3 Whereas PI3K/AKT signalling has been mainly associated with beneficial, physiological growth, hypertrophy mediated by calcineurin/NFAT activation has been interpreted as maladaptive reponse. 4, 5 FoxO transcription factors are important downstream targets of the PKB/AKT pathway and are characterized by the highly conserved Forkhead domain. 6, 7 They maintain a central role in cell physiology, regulate diverse processes, and have been particularly associated with stress resistance, apoptosis, cell cycle arrest, response to DNA damage, glucose metabolism, and cellular atrophy. Typically, FoxO factors are activated in the absence of growth factors and under cellular stress conditions. Control of FoxO activity mainly occurs on the post-translational level by phosphorylation, acetylation, and ubiquitination, which result in an alteration in subcellular localization, transcriptional activity, or in protein stability. 7 In the heart, two members of the FoxO family, FoxO1 and FoxO3, show a high expression. 8 Both FoxO1 and FoxO3 can be phosphorylated by AKT at three conserved amino acids, which results in its nuclear export and sequestration in the cytoplasm. In contrast, FoxOs can be activated under oxidative stress conditions via JNK-mediated phosphorylation, or under fasting conditions via AMPK-mediated phosphorylation. 7 FoxO transcription factors regulate cardiomyocyte proliferation and cardiac growth during development. 9 -11 In cultured neonatal rat cardiomyocytes, FoxO1 and FoxO3 can reduce the activity of calcineurin, which governs a crucial hypertrophic pathway. 12 Interestingly, FoxO32/2 mice display a mild increase in heart size and weight, suggesting an anti-growth effect of FoxO3 in vivo. 12 In the skeletal muscle, activation of FoxO3 leads to atrophy by shifting the balance from protein synthesis to protein degradation. 13 This shift has been shown to involve an activation of both the ubiquitinproteasomal and autophagic-lysosomal pathways. 13 -15 There is evidence that FoxO3 in the heart can act in a manner similar to its function in the skeletal muscle, by both directly inducing the ubiquitin ligase atrogin 16 and augmenting autophagy. 17 Although there is increasing knowledge about the effects of FoxO in cultured cardiomyocytes, thus far the elucidation of FoxO function in adult mice in vivo has been hampered by the embryonic lethality of transgenic activation of both FoxO1 and FoxO3. 9 However, it is likely under these precise conditions that insights of relevance for human disease can be gained. Thus, for this study, we generated a new mouse model with inducible heart-specific expression of a constitutively active mutant of FoxO3. We show that the constitutive activation of FoxO3 leads to a reduction in heart size, which is accompanied by a reduction in stroke volume. Cardiomyocytes of affected hearts are smaller because of reduced individual cell size, show myofibrillar disarrangement, and manifest signs of mitochondrial degeneration and autophagy.
Methods
Detailed methods are available in Supplementary material online.
Mice
Mice were generated by pronuclear microinjection of a bidirectional vector containing FoxO3-CA cDNA (T32A, S256A, and S308A, provided by Marc Schmidt, the Netherlands Cancer Institute) and luciferase cDNA under the control of the Tet operon. 18, 19 These mice were crossed with mice expressing the tetracycline transactivator under the control of the a-myosin heavy chain promoter. 20 All animal experiments were in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and the German Animal Protection Act and were approved by the responsible government agency (Regierungspräsidium Tübingen, Versuch-Nr. 1018, and Regierungspräsidium Darmstadt, Versuch-Nr. V54-19c20/15-B2/223).
In vivo bioluminescence imaging
Anaesthetized and luciferin-injected mice were examined in an IVIS 200 System (Caliper).
Magnetic resonance imaging
Isoflurane-anaesthetized mice were examined in a Bruker Pharmascan 7.0 T. Multiple contiguous short-axis slices consisting of six to eight slices were acquired for complete coverage of the left ventricle. 21 Magnetic resonance imaging (MRI) data were analysed with Qmass digital imaging software (Medis).
Transverse aortic constriction
Mice were kept without doxycycline, allowing full development of cardiac atrophy in FoxO3 MyHC mice. Mice were anaesthetized with isoflurane, endotracheally intubated with a 20 G catheter (Braun, Germany) and ventilated (MiniVent, HSE, Germany). The transverse aortic arch was surgically accessed and ligated (Prolene 7-0) between the right innominate and left common carotid arteries with an overlying 24 G needle. The needle was then removed, leaving a stenosis. Sham-operated mice underwent the same surgical procedure without the actual ligation. Mice were killed for analysis 4 weeks after surgery.
Adult murine cardiomyocyte isolation
Intraperitoneally, 60 IU heparin and 20 mg xylazin/125 mg ketamine per kg body weight were injected for anti-coagulation and narcosis. Hearts were excised, a 23 G hypodermic needle was inserted in the aorta, and digestion was started by retrograde Langendorff perfusion with a calcium-free buffer supplemented with 6.5 mg/mL Liberase DH (Roche) and 3.5 mg/mL trypsin (Sigma). After addition of foetal calf serum and tissue dissociation, cells were filtered through a 100 mm mesh. Calcium was re-introduced, and cells were seeded on laminin-coated six-well culture dishes.
Histological analysis
Organs were frozen in liquid nitrogen for cryosections, or incubated in phosphate-buffered saline (PBS)-buffered formalin, dehydrated, and embedded in paraffin. Cryosections were cut in 5 mm sections and fixed with PBS/4% paraformaldehyde. Paraffin sections were cut in 3 mm sections, deparaffinized, and rehydrated. Sections were blocked and incubated with antibodies against FoxO3 (Santa Cruz) and sarcomeric actinin (Sigma) over night at 48C, and then with secondary antibodies (coupled with Alexa Fluor 488 or 596) for 1 h at room temperature. TUNEL staining was performed with an in situ TUNEL detection kit (Roche).
Transmission electron microscopy
Left ventricular tissue of control or FoxO3 MyHC mice was fixed in 2.5% glutaraldehyde in 0.1 mol/L cacodylate buffer, post-fixed in 2% OsO 4 in cacodylate buffer, dehydrated, bloc-stained in 2% uranyl acetate in ethanol, and flat-embedded in Epon. Seventy-nanometer sections were stained with lead citrate and mounted on copper grids. Adult murine cardiomyocytes grown for 36 h in the absence of doxycycline on laminin-coated, glow-discharged sapphire discs were high-pressure frozen, freeze-substituted, and embedded in Epon.
Protein extraction
Organs were snap frozen in liquid nitrogen and pulverized. Tissue for SDS -PAGE was lysed in RIPA buffer. For luciferase activity, TNT extracts (0.1 mol/L Tris -HCl, 0.15 mol/L NaCl, and 0.05% Triton X-100) were analysed in a luminometer with luciferin-containing buffer.
Western blotting
Ten to 50 mg of protein were separated by SDS -PAGE and transferred onto PVDF membranes, which were blocked and incubated with antibody. Bands were detected by horseradish peroxidase-coupled secondary antibody and chemiluminescence. Table S3 ). Rpl13 was used as a reference for relative quantification.
Gene expression profiling
Total RNA was isolated using the mirVana isolation kit (Ambion). For both genotypes, four biological replicas were analysed on a Mouse Gene 1.0 ST GeneChip (Affymetrix).
Results
3.1 Generation of transgenic mice with inducible heart-specific expression of constitutively active FoxO3
We generated transgenic mice carrying a constitutively active FoxO3 allele and the coding sequence of luciferase under the control of a bidirectional tetracycline-regulated promoter. These animals were crossed with mice expressing the tetracycline transactivator under the control of the a-myosin heavy chain promoter (see Supplementary material online, Figure S1A ). No live double-transgenic animals (FoxO3 MyHC ) were born when FoxO3 was expressed during embryogenesis, consistent with previous reports. 9 In contrast, FoxO3
MyHC mice were obtained in normal Mendelian ratios when the transgenic system was inactivated by administration of doxycycline. We performed in vivo chemiluminescence imaging to determine the specificity and the kinetics of transgene expression ( Figure 1A ; see Supplementary material online, Figure S1B and C). Luciferase activity as a surrogate marker for FoxO3-CA expression was detected 2 weeks after doxycycline withdrawal in adult mice and reached a plateau after 6 weeks (see Supplementary material online, Figure S1C ). Immunoblots for luciferase showed expression specifically in the hearts of FoxO3-MyHC animals. FoxO3 is known to be highly expressed in the heart; these already high protein levels were enhanced (about two-fold) in the hearts of FoxO3 MyHC animals (see Supplementary material online, Figure S1D ).
FoxO3-CA reduces heart size and weight

When FoxO3
MyHC mice were analysed after prolonged (≥6 weeks) transgene activation, a reduced overall heart size and dilated auricles were apparent ( Figure 1B ). Since other organs and body weight were not affected (see Supplementary material online, Figure S2 ), the reduced heart size resulted in a reduced heart weight to body weight (HW/BW) ratio ( Figure 1C , left). In the presence of doxycycline, no abnormal heart weight or HW/BW ratio was observed. Already 4 weeks after doxycycline removal, there was a tendency towards a reduced heart weight and HW/BW ratio, and after 6 weeks, both heart weight and HW/BW ratio were decreased by 25% ( Figure 1C ). In general, no further reduction in heart size was observed in mice kept without doxycycline for 20 weeks.
In order to assess morphology and function of the altered hearts in vivo, we performed cardiac MRI. Mice were kept under doxycycline until young adulthood, when their normal hearts were examined in a first MRI ( Figure 1D and E). After a period of 20 weeks of doxycycline removal, the same mice were examined in a second MRI. The stroke and end-diastolic volumes of the left ventricle were decreased by 20% in mice expressing FoxO3-CA, whereas the ejection fraction remained unchanged. Since the heart rate was unaltered, cardiac output was reduced by 20% ( Figure 1E ).
Cardiac remodelling in FoxO3
MyHC animals Pathological changes in the heart are often associated with the reactivation of a foetal gene programme and increased actin remodelling. In FoxO3
MyHC mice, a-smooth muscle actin (a-SMA), an actin isoform typically expressed in the embryonic heart, and destrin, a protein involved in actin depolymerization, were up-regulated in affected hearts ( Figure 2A) . Also, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) transcripts were up-regulated in FoxO3 MyHC animals ( Figure 2B ). Another typical alteration in diseased hearts is the switch in myosin heavy chain isoforms. Whereas a-myosin heavy chain is characteristic for adult mouse cardiomyocytes, the b-myosin heavy chain predominates in early murine development. By quantitative PCR, we found a strongly decreased a-to b-myosin heavy chain ratio, indicative of foetal reprogramming ( Figure 2C ). We wondered whether PKB/AKT signalling, which can mediate hypertrophy and cytoprotection upstream of FoxO, was activated in our mice. Levels of phosphorylated PKB/AKT (both Ser-473 and Thr-308)-and hence active kinase-were increased strongly in Fox-O3
MyHC animals ( Figure 2D ; for quantification, see Supplementary material online, Figure S3A ). Of the downstream pathways of PKB/ AKT other than FoxO, the mammalian target of rapamycin (mTOR) was activated, as indicated by the phosphorylation of mTOR and S6 ribosomal protein (S6RP). 4E-BP, which may inhibit translation downstream of FoxO, 22 was up-regulated but at the same time increasingly phosphorylated-and thus, inactivated. We did not detect an increase in GSK3b phosphorylation, a downstream target of PKB/AKT which is inactivated by phosphorylation. Similar results, particularly the effect on S6RP, were obtained in cardiomyocytes of FoxO3 MyHC mice where the transgene was activated ex vivo (see Supplementary material online, Figure S3B ). In summary, we conclude that AKT signalling and some of its downstream pathways are activated in atrophic FoxO3 MyHC hearts, which may mediate compensatory hypertrophy and/or cell survival.
FoxO3 activation affects size and structure of cardiomyocytes
The observed reduction in heart size could be a consequence of either a reduction in cell number or in cell size. In order to determine possible differences in cell size, we stained cryosections of hearts with wheat germ agglutinin for the demarcation of cell boundaries. A comparison of control sections and sections from FoxO3 MyHC animals revealed that cell size in FoxO3 MyHC hearts was strongly reduced ( Figure 3A) . A cell size quantification of cardiomyocytes isolated from control and FoxO3 MyHC hearts confirmed that the area of transgenic cardiomyocytes was indeed 40% smaller than that of their wildtype counterparts ( Figure 3A, right) . In contrast, apoptosis in FoxO3-MyHC hearts was not enhanced ( Figure 3B ). In sections stained with haematoxyline and eosin, a disarrangement of myofibrils and perinuclear loss of cell organelles in FoxO3 MyHC hearts was obvious ( Figure 3C ).
FoxO3 induces cardiac atrophy
Ultrastructural disorganization and degeneration in FoxO3 MyHC hearts
In order to obtain a detailed insight into the organization of myofibrils and sarcomeres, we performed electron microscopy. Ventricular tissue of FoxO3 MyHC mice showed obvious myofibrillar disarrangement, thinning of sarcomeres, and loss of the typical alignment of contractile structures and mitochondria (see Supplementary material online, Figure S4A and B).
As high-pressure freezing of isolated cells allows for improved ultrastructural preservation, we in addition performed analyses on isolated cardiomyocytes. Adult cardiomyocytes were isolated from mice kept under doxycycline and cultivated without doxycycline for 36 h, allowing the transgene to be activated in vitro. Under these conditions, we observed a massive disarrangement of myofibrillar structures and destruction of sarcomeres similar to the changes observed in vivo (Figure 4A-C; see Supplementary material online, Figure S4C and D). The loss of organelles was particularly prominent in the perinuclear region (see Supplementary material online, Figure  S4E and F). Also, FoxO3
MyHC cells showed massive degeneration of mitochondria, characterized by dilation of cristae. Also, many mitochondria were surrounded by membranes, suggesting an autophagic process. In reconstructed tomograms, the striking mitochondrial phenotype was particularly obvious (see Supplementary material online, Video Files tomogram_control and tomogram_transgenic). Quantification of the ultrastructural data revealed that in FoxO3 MyHC cardiomyocytes, the proportion of degenerated mitochondria was increased from 6 to 30% and that of clearly autophagic mitochondria from 0.3% to almost 7% ( Figure 4D ). This finding was confirmed by a quantification of mitochondrial DNA relative to genomic DNA, which was reduced by 26% in FoxO3 MyHC hearts when compared with control hearts ( Figure 4E) . Similarly, expression of proteins involved in mitochondrial biogenesis and metabolism was reduced (see Supplementary material online, Figure S5A and B). An important regulator of the expression of these genes, peroxisome proliferatoractivated receptor g-coactivator 1a, was however unchanged (data not shown).
Mechanisms of FoxO3-induced cardiac atrophy
To characterize the molecular events induced by activation of FoxO3, we performed a microarray analysis on Table S1 ). This might be due to the advanced disease stage where an extensive counter-regulation already had taken place. Thus, in order to characterize early and more proximal events in FoxO3
MyHC cardiomyocytes, we performed a gene expression analysis under the same conditions already employed for electron microscopy. Adult cardiomyocytes were isolated from mice kept under doxycycline and then allowed to activate the transgene. Gene array analysis was performed 36 h after doxycycline removal, when luciferase values were high (see Supplementary material online, Figure S6A) , and revealed the up-regulation of several known FoxO target genes, including Gadd45a, Sestrin3, and Pdk4 23, 24 (see Supplementary material online, Table S2A ). Consistent with the observed phenotype, genes involved in autophagy were up-regulated, e.g. LC3b, Bnip3, Bnip3l (Nix), Gabarapl1, and Ulk1. Results obtained by the microarray analysis were confirmed by quantitative RT-PCR (Figure 5A and B; Supplementary material online, Figure S6B ). Figure S3 . *P , 0.05; **P , 0.01; ***P , 0.001.
FoxO3 induces cardiac atrophy LC3 protein exists in a free (LC3-I) and in an active, membrane-bound form (LC3-II). LC3-II was increased in FoxO3
MyHC cardiomyocytes after ex vivo transgene activation ( Figure 4F ; see Supplementary material online, Figure S6C ). Treatment with lysosomal inhibitors revealed that LC3-II levels could still be stimulated in FoxO3 MyHC cardiomyocytes, indicating an activation of autophagy rather than a disturbance in autophagic flux. A similar result was obtained in vivo by chloroquine treatment of control and FoxO3 MyHC mice (see Supplementary material online, Figure S6C ). Of the up-regulated genes in our screen, Bnip3 had been previously associated with FoxO-induced atrophy and autophagy 14, 15 . Both forms of BNIP3 protein, the monomeric, inactive and the dimeric, active form, were up-regulated in FoxO3
MyHC hearts ( Figure 5B ).
Inactivation of transgene expression leads to phenotype reversal
Continuous activation of FoxO3 had resulted in smaller hearts with smaller cardiomyocytes but without detectable levels of increased cell death. We thus wondered whether inactivation of transgene expression in diseased animals by re-administration of doxycycline could reverse the phenotype. Therefore, FoxO3-CA expression was repressed for 3 weeks in mice that previously had activated the transgene. Hearts from these mice were indistinguishable from control hearts, whereas hearts from animals in which transgene expression was not inactivated showed the expected reduction in heart size ( Figure 6A) . MRI analyses on a cohort of animals showed a recovery of functional parameters, e.g. normalization of stroke volume, end-diastolic volume, and cardiac output ( Figure 6B and C ). Recovery was also observed on the molecular level after 4 weeks of transgene inactivation. Expression levels for ANP and BNP were almost reduced back to control levels ( Figure 6D ). In addition, the mRNA levels of myosin isoforms were comparable to those typical of controls, suggesting that hearts were able to recover from effects caused by prolonged activation of FoxO3 ( Figure 6D ). Taken together, our results demonstrate that the pathology associated with FoxO3 induces cardiac atrophy expression of a constitutively active FoxO3 allele in the heart is fully reversible by the ablation of transgene expression.
FoxO3-CA cannot block hypertrophy induced by pressure overload
FoxO3 activation may not only cause atrophy, but also counteract hypertrophy. We therefore subjected FoxO3 MyHC mice to pressure overload induced by transverse aortic constriction (TAC). Control and FoxO3 MyHC mice showed a comparable response to TAC, with a 20% increase in the HW/BW ratio compared with sham-operated mice ( Figure 6E) . Also, changes in wall thickness as assessed by MRI were comparable (see Supplementary material online, Figure S7A and B).
Discussion
FoxO transcription factors are increasingly being recognized as central regulators of heart plasticity. Here, we demonstrate that heart-specific activation of FoxO3 leads to a strong reduction in organ size by diminishing the size of individual cardiomyocytes. The course of FoxO3-induced cardiomyopathy followed a certain pattern. The first weeks after doxycycline withdrawal showed increasing transgene activity over a period of 6 weeks, which probably reflected (black bars) and of age-matched control animals (white bars). Right: Heart weight relative to tibia length of sham-and TAC-operated FoxO3
MyHC animals (black bars) and of age-matched control animals (white bars) (n ≥ 4 per genotype). *P , 0.05; **P , 0.01; ***P , 0.001.
FoxO3 induces cardiac atrophy a wash-out effect of doxycycline. As soon as FoxO3-CA expression had reached its plateau, the reduction in heart mass reached its full extent. The ejection fraction remained at normal levels, but cardiac output was decreased due to a decreased stroke volume. The fact that heart mass was not further decreased over time could be either explained by a self limitation of the FoxO effects themselves or by the activation of compensatory hypertrophic pathways. FoxO3-induced cardiomyopathy was accompanied by reactivation of a foetal gene programme, including up-regulation of ANP and BNP, and a switch from a-to the b-isoform of myosin heavy chain. Interestingly, FoxO3-induced cardiomyopathy was functionally reversible, with a quick normalization of the stroke volume within 3 weeks of transgene inactivation. This observation suggests that the regulation of myocardial growth is a fast and dynamic process.
In our model, constitutive activation of FoxO3, while promoting cardiac atrophy at baseline, could not counteract pathological hypertrophy induced by TAC. Still, the weight of FoxO3
MyHC hearts after TAC was smaller than that of their wild-type counterparts, but the relative increase compared with sham-operated hearts was comparable. Thus, distinct pathways seem to be responsible for the induction of baseline atrophy and the block of hypertrophy. Similarly, cardiacspecific knockout of the insulin receptor upstream of FoxO signalling leads to heart atrophy without a block in the induction of hypertrophy. 25 The cell size of cardiomyocytes is tightly regulated and ultimately depends on the balance of protein synthesis and degradation. FoxO factors can shift this balance by activating protein degradation. This can principally be achieved either by activation of the ubiquitin-proteasome system or by induction of autophagic-lysosomal degradation.
Fundamental for the ubiquitin-proteasome system in the muscle are two atrophy-promoting ubiquitin ligases, atrogin-1/MAFbx and MuRF1. Sandri et al. 13 have shown in the skeletal muscle that FoxO3 can directly induce the transcription of atrogin-1 and that this pathway can be controlled via an IGF-1/PI3K/AKT signalling axis. Skurk et al. 16 later showed that the same mechanism can also lead to a decrease in size of cardiomyocytes. In our model, we also detected an up-regulation of atrogin-1 mRNA; however, this regulation was weak and statistically not significant. This finding may support the hypothesis that FoxO3-induced atrophy in the heart is at least in part mediated by other pathways; however, we cannot rule out a contribution of atrogin-1 and proteasomal degradation. Autophagy is a lysosomal pathway independent of the ubiquitinproteasome system, and it is emerging as a process central to the homeostasis of myocytes. It is essential for clearing cellular damage, but also for the reallocation of resources in the case of nutrient deprivation. For example, vital proteins can be synthesized out of amino acids generated by the breakdown of organelles, a process crucial for the survival during periods of starvation. 26 In FoxO3 MyHC cardiomyocytes, the number of autophagosomes was increased. This finding is in line with studies in the skeletal muscle, where FoxO3 was shown to control autophagy, 14, 15 and experiments in cultured rat neonatal cardiomyocytes in which the authors showed that FoxO3 can induce autophagy. 17 Autophagy in FoxO3 MyHC cardiomyocytes mainly targeted mitochondria, many of which were found engulfed by membranes. However, in addition to clearly autophagic mitochondria, there were high numbers of degenerated mitochondria not engulfed by membranes. It is an interesting question whether this degeneration is in some way linked to autophagy or whether it represents an independent event.
Classical autophagy is regulated by a set of autophagy-related genes. In our model, transcription of several of these genes was significantly up-regulated, most importantly Lc3b and Ulk1, whereas the up-regulation of others was not significant (Atg12, Beclin1, and Gabarapl1). Some of these genes had been identified as FoxO3 target genes, e.g. Lc3b, Gabarapl1, and Atg12. 14, 15 On the protein level, the expression of the active, membrane-bound form of LC3 protein (LC3-II) was increased both in vitro and in vivo. As autophagic flux was not affected, this can be interpreted as evidence for increased autophagy upon FoxO3 activation. However, LC3 up-regulation alone is not considered to be sufficient for triggering autophagy and may even not be necessary for all types of autophagy. 26, 27 The BH3-only proteins BNIP3 and BNIP3L, whose transcription is also FoxO3-dependent, are also important candidate mediators of the observed FoxO3 effects. BNIP3 is a potent inductor of autophagy in the heart 28 and has been suggested to act as the main mediator of FoxO3-induced atrophy in the skeletal muscle, because Bnip3 knockdown attenuates FoxO3-induced autophagy. In addition, FoxO3 binding to the Bnip3 promoter is enhanced under atrophic conditions, indicating a direct activation of Bnip3 by FoxO3. 15, 29 It is conceivable that FoxO3 governs a similar pathway in the heart muscle. In addition to their autophagy-promoting role, BNIP3 and BNIP3L can promote cell death via apoptosis or necrosis. In the heart, cell death typically leads to ventricular dilation. Mice with cardiac-specific overexpression of BNIP3 or BNIP3L, for example, suffer from heart dilation. 30, 31 In contrast, we could not detect an increase in cell death in our model, and the hearts were significantly smaller. Moreover, the reversibility of the FoxO3 MyHC phenotype might argue for a process flexible in both directions, which in the heart is true for atrophy, but not for cell death. It is therefore likely that FoxO3 in the adult heart mainly counteracts cell growth and does not lead to cell death in vivo. This hypothesis is supported by the finding that cardiomyocyte size is decreased upon FoxO3 gene transfer into mouse hearts, but apoptosis is not enhanced. 16 Constitutive activation of FoxO3 in the hearts of living animals not only leads to atrophy, but also induces the activation of pathways known to mediate cell survival and hypertrophy. For example, phosphorylation of PKB/AKT was enhanced at both Ser-473 and Thr-308, indicating an increased kinase activity. This regulation might be seen as part of a feedback loop, where hyperactivated FoxO3 activity triggers activation of its upstream kinase AKT, which in turn inactivates FoxO3 by phosphorylating it. 32 However, since our mouse model uses a FoxO3 mutant where the amino acids targeted by AKT are mutated, the increased AKT activity cannot counteract FoxO activation. In addition to FoxOs, AKT, of course, has other downstream targets, among them mTOR. Indeed, phosphorylation of mTOR was slightly increased, and, more importantly, phosphorylation of S6RP, a marker of the activity of the mTOR pathway, was strongly enhanced. In cultured neonatal cardiomyocytes, it was reported that FoxO3 activation leads to AKT phosphorylation, but not to the activation of the usual downstream pathways. 32 In contrast, we could readily detect an increased phosphorylation of S6RP and of 4E-BP, both in whole hearts and in cardiomyocytes in which the transgene had been activated ex vivo. Activation of the mTOR pathway usually leads to enhanced protein synthesis, e.g. by the action of S6RP, which augments translation and ribosomal biogenesis. Another target of mTOR is the antihypertrophic kinase GSK3b, which can be inactivated by mTORmediated phosphorylation. However, we did not detect a change in its phosphorylation status. In summary, activation of AKT and mTOR can be interpreted as cytoprotective events, or as an indication of compensatory hypertrophy. Although FoxO3 MyHC hearts can compensate only in a limited manner for the atrophy initiated by the hyperactivation of FoxO3, activation of mTOR signalling may still prevent excessive atrophy. 33 In conclusion, our study shows that FoxO3 induces heart atrophy in vivo by decreasing the size of individual cardiomyocytes. Our data suggest an involvement of mitochondrial degeneration and autophagy in this process. BNIP3 might be a mediator of some of these effects, but other pathways may also contribute to the observed phenotype. Interestingly, clinical data also provide evidence for a prominent role of FoxOs in the restriction of cardiac growth. For example, FoxO3 mRNA was up-regulated in a study on human patients who had received left ventricular assist device support of their failing hearts. 34 Understanding the mechanisms of heart atrophy will eventually also help understand pathological heart hypertrophy and hopefully provide new concepts for targeted therapies.
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